Will a new non-hormonal menopause treatment receive full FDA approval in 2026?
Current Probability
68%
261 days left
$12,450 volume
This market resolves YES if the FDA grants full approval (not just EUA or fast-track designation) to a non-hormonal pharmaceutical treatment specifically indicated for menopause symptoms before December 31, 2026.
FDA grants full approval to a non-hormonal drug specifically for menopause symptoms. Verified via FDA.gov press releases.
Important Disclaimer
This prediction market uses play-money beta credits with no cash value. Odds reflect crowd sentiment, not certainty. This is not financial, medical, or investment advice. Resolution is determined solely by the pre-stated criteria and source listed above.
This is a play-money prediction market using beta credits with no cash value. Not financial, medical, or investment advice. Trade responsibly.